Skip to main content
. 2020 Apr 24;9(2):LMT31. doi: 10.2217/lmt-2020-0008

Table 4. . Adverse events for the entire subject cohort.

Adverse events Total (n = 106)
  All grades Grade 3/4
Total 96 (90.6%) 3 (2.8%)
Fatigue/weakness 58 (54.7%) 1 (0.9%)
Diarrhea/colitis 16 (15.1%) 0 (0%)
Hypophysitis 0 (0%) 0 (0%)
Thyroid 11 (10.4%) 0 (0%)
Adrenal insufficiency 1 (0.9%) 0 (0%)
Pneumonitis 6 (5.7%) 2 (1.8%)
Rash/pruritis 17 (16.0%) 0 (0%)
Liver 2 (1.8%) 0 (0%)
Nephropathy 9 (8.5%) 0 (0%)
Dyspnea 23 (21.7%) 0 (0%)
Edema 11 (10.4%) 0 (0%)
Constipation 9 (8.5%) 0 (0%)
Nausea/vomiting 14 (13.2%) 0 (0%)
A fib 1 (0.9%) 0 (0%)
Arthralgia/myalgia 10 (9.4%) 0 (0%)
Pneumonia/upper respiratory infection 12 (11.3%) 0 (0%)
Flu like symptoms 2 (1.8%) 0 (0%)
Hypersensitivity reaction 1 (0.9%) 0 (0%)
Other 10 (9.4%) 0 (0%)
Discontinued due to adverse event 20 (18.9%)